title: Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes.
abstract: OBJECTIVE
  Eradication of Helicobacter pylori is more difficult in adult patients with diabetes than in patients with dyspepsia. It has also been suggested that eradication of H. pylori in children with type 1 diabetes mellitus improves their metabolic control. The aim of the current study was to assess the eradication rate of a standard triple therapy and its effects on glycemic control in young patients with type 1 diabetes.
  
  
  METHODS
  The authors enrolled 29 type 1 diabetic patients with H. pylori, 29 type 1 diabetic patients without H. pylori, and 29 dyspeptic children with H. pylori. Groups were matched for gender and age and had similar geographical origin and socioeconomic status. H.pylori status was investigated before and 6 weeks after therapy by C-urea breath test. All enrolled patients with H. pylori were prescribed a standard triple therapy for eradicating H. pylori. Glycosylated hemoglobin A and daily insulin requirement were evaluated at enrollment and 6 months later in all patients with diabetes. The prevalence of the most common gastrointestinal symptoms also was investigated by means of a questionnaire in all subjects at enrollment and 6 months later.
  
  
  RESULTS
  Eradication of H. pylori was similar in patients with diabetes (24/29) and those with dyspepsia (23/29) (83%v 79%; P = NS). No difference in metabolic control was observed before or after antibiotic treatment in the patients who experienced H. pylori eradication. No difference in glycemic control was observed after 6 months of follow-up.
  
  
  CONCLUSIONS
  The eradication rate of H. pylori infection was similar for young patients with type 1 diabetes and those with dyspepsia and did not improve metabolic control in a short-term follow-up.
authors.affiliation: Department of Internal Medicine, Università Cattolica Sacro Cuore, Rome, Italy.
authors.forename: Marcello
authors.initials: M
authors.lastname: Candelli
authors.forename: Donato
authors.initials: D
authors.lastname: Rigante
authors.forename: Giovanni
authors.initials: G
authors.lastname: Marietti
authors.forename: Enrico C
authors.initials: EC
authors.lastname: Nista
authors.forename: Francesca
authors.initials: F
authors.lastname: Crea
authors.forename: Alessandra
authors.initials: A
authors.lastname: Schiavino
authors.forename: Giovanni
authors.initials: G
authors.lastname: Cammarota
authors.forename: Giulia
authors.initials: G
authors.lastname: Pignataro
authors.forename: Stefano
authors.initials: S
authors.lastname: Petrucci
authors.forename: Giovanni
authors.initials: G
authors.lastname: Gasbarrini
authors.forename: Antonio
authors.initials: A
authors.lastname: Gasbarrini
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism*; D001944:Breath Tests; D002648:Child; D002675:Child, Preschool; D017291:Clarithromycin / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism* / Q000382:microbiology; D004415:Dyspepsia / Q000378:metabolism* / Q000382:microbiology; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D064750:Rabeprazole; D013997:Time Factors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D001562:Benzimidazoles; D001786:Blood Glucose; D064750:Rabeprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole